Daylight Savings linked to increased medical errors

Article

Human errors including medications, administering either the wrong dose or the wrong drug, seem to increase by 18 percent

Although the U.S. is about to “fall back” with the end of 2020’s Daylight Savings Time (DST), research has showed that the start of DST may be behind medical errors.

Medical errors are more likely to occur in the days following the “spring ahead” DST switch, an observational study found.1

As part of the Mayo Clinic Health System, healthcare workers are encouraged to voluntarily report patient safety-related incidents caused by defective systems, equipment, or human error. The data collected from this record of reports was examined for errors in the 7 days preceding and following the spring and fall time changes, over a period of 8 years.

By and large, there were no substantial differences in errors reported in the weeks before and after DST. However, when researchers constrained their analysis to only human errors, they found a statistically significant increase of 18.7 percent human errors when an hour was lost in the spring. The majority of errors occurring during this time involved medications, administering either the wrong dose or the wrong drug.

When it came to the fall switch back to standard time, when an hour is gained, there were no significant differences in human errors in the weeks preceding and following DST.

Delayed start times and other contingency measures are suggested to help mitigate the increased risk of errors in the spring.

Do you plan to hand out candy to trick or treaters this Halloween, during the pandemic?

Reference

1. Kolla BP, Coombes BJ, Morgenthaler TI, Mansukhani MP. Increased Patient Safety-Related Incidents Following the Transition into Daylight Savings Time. J Gen Intern Med. 2020. DOI: s11606-020-06090-9.

Recent Videos
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.